Bristol-Myers Squibb
BMY
BMY
1,733 hedge funds and large institutions have $71.6B invested in Bristol-Myers Squibb in 2017 Q4 according to their latest regulatory filings, with 194 funds opening new positions, 605 increasing their positions, 677 reducing their positions, and 82 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
3% less capital invested
Capital invested by funds: $73.8B → $71.6B (-$2.14B)
11% less repeat investments, than reductions
Existing positions increased: 605 | Existing positions reduced: 677
22% less funds holding in top 10
Funds holding in top 10: 58 → 45 (-13)
Holders
1,733
Holding in Top 10
45
Calls
$2.02B
Puts
$1.81B
Top Buyers
| 1 | +$303M | |
| 2 | +$230M | |
| 3 | +$212M | |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
+$158M |
| 5 |
D.E. Shaw & Co
New York
|
+$133M |
Top Sellers
| 1 | -$584M | |
| 2 | -$342M | |
| 3 | -$167M | |
| 4 |
Jennison Associates
New York
|
-$140M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$138M |